What exactly is Zepbound, as distinct from tirzepatide?
Zepbound is one approved product, while tirzepatide is the molecule inside it. The FDA approved Zepbound on 8 November 2023 for chronic weight management, and noted that the same active ingredient was already approved as Mounjaro [2]. The label, revised in August 2026, lists two uses: long-term weight reduction in adults with obesity, or with overweight and at least one related condition, and moderate to severe obstructive sleep apnea in adults with obesity [1].
An approval covers a product: its formula, its maker and its quality checks. A pharmacy that mixes tirzepatide has not made Zepbound, and the label says Zepbound should not be combined with "other tirzepatide-containing products" [1]. On our tirzepatide record, the molecule holds the top grade, with 8 or more completed randomized trials. Those trials tested the maker's product.
Is compounded tirzepatide FDA approved?
Compounded tirzepatide is not FDA approved, and the agency says so in plain words: "compounded drugs are not FDA approved" [4]. The same page explains what that means: the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed" [4].
The FDA does see a place for compounding. It says a compounded drug "might be appropriate if a patient's medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available" [4]. That is a narrow door. It is not a stamp on any vial.
Was compounded tirzepatide ever allowed, and is it now?
Compounded tirzepatide was tolerated on a wide scale for one reason: a shortage, and the shortage is over. On 19 December 2024 the FDA decided that "the tirzepatide injection shortage is resolved" [3]. It then gave compounders time to stop. State-licensed pharmacies had until 18 February 2025. Larger outsourcing facilities had until 19 March 2025 [3]. In its update of April 2026, the FDA wrote that tirzepatide does not appear on its shortage list [3].
On 30 April 2026 the FDA went further. It proposed to keep semaglutide, tirzepatide and liraglutide off the list of bulk ingredients that outsourcing facilities may use, "finding no clinical need" [5]. The FDA commissioner said: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need" [5]. The FDA asked for comments by 29 June. As of October 2026 we found no final decision.
What has the FDA found going wrong with compounded tirzepatide?
The FDA has logged more than 730 side-effect reports tied to compounded tirzepatide, as of 31 May 2026 [4]. It adds a warning about that number: federal law does not require ordinary state-licensed pharmacies to report side effects to the FDA, "so it is likely that adverse events from compounded versions of these drugs are underreported" [4]. The real count is unknown.
The FDA also describes fakes. It knows of "fraudulent compounded semaglutide and tirzepatide" with false labels, and in some cases "the compounding pharmacies identified on the labels of the products do not exist" [4]. One report came from a product "labeled as compounded tirzepatide from a pharmacy that did not actually compound the product" [4]. A pharmacy name on a label proves nothing on its own. Our page on how to read a certificate of analysis covers the paper that should come with a lot.
Does the same name mean the same thing in the vial?
The same name on a label does not mean the same product in the vial. Nobody outside a lab can see what a vial holds. For semaglutide, the sister drug, a 2024 study of no-prescription online orders found purity of 7% to 14% against an advertised 99%. We tell that story in six semaglutide orders, three arrivals. We found no study of the same kind for tirzepatide. That is a gap. It is no proof either way.
The other side
Compounding is a real part of medicine, and the FDA itself says it can be right when an approved drug cannot meet a patient's need [4]. Many of the side effects reported for compounded versions look like the ones known for the approved drugs, the FDA says [4]. None of that makes a compounded product the same as Zepbound. It means the label alone cannot say which kind of product is in the vial.
What would change this answer?
- A final FDA decision on the April 2026 proposal, either way.
- A new shortage of tirzepatide on the FDA's list.
- A published lab comparison of compounded tirzepatide from licensed pharmacies against Zepbound's approved quality standards.
Three questions to ask next
Every source below was opened and checked on 11 Oct 2026.
- [1] Zepbound (tirzepatide) prescribing information, revised 8/2026 (opens in new tab). Eli Lilly and Company, on DailyMedBack to text (first mention of source 1)
- [2] FDA approves new medication for chronic weight management (opens in new tab). FDA press announcement, 8 November 2023Back to text (first mention of source 2)
- [3] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (opens in new tab). FDA, content current as of 1 April 2026Back to text (first mention of source 3)
- [4] FDA's concerns with unapproved GLP-1 drugs used for weight loss (opens in new tab). FDA, content current as of 1 October 2026Back to text (first mention of source 4)
- [5] FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list (opens in new tab). FDA press announcement, 30 April 2026Back to text (first mention of source 5)
- [6] Tirzepatide record, checked 22 September 2026 (opens in new tab). The Peptide Table Secondary